Sirnaomics is a biopharmaceutical company developing oncology therapeutics by using RNA interference (RNAi) technology. It uses a proprietary discovery platform to develop therapies that utilize two short segments of RNA, known as short interfering, or silencing RNA (siRNA), to defeat proteins involved in the progression of certain diseases.